In this review, the authors aim to provide an overview of current molecular targeted therapies
for NSCLC, to propose an algorithm for clinical application of presently available treatment …

Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic
profiling has allowed for the characterization of its molecular subtypes. This has increased …

With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the
development of innovative treatment strategies is increasingly vital. This review underscores …

Globally, lung cancer is the leading cause of cancer-related mortality among both men and
women, and while mortality associated with the disease has demonstrated relative stability …

Lung cancer remains the leading cause of malignancyrelated mortality worldwide with over
a million cases diagnosed yearly. Non-small cell lung cancer (NSCLC) accounts for more …

Even with the introduction of targeted agents and the establishment of multiple lines of
therapy, the median survival for patients with advanced non-small cell lung cancer (NSCLC) …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Lung cancer is the most common malignancy in the US and causes the most cancer-related
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …

Although tumor molecular-profile-directed therapy appears promising in early clinical
studies, there are many practical challenges to its successful clinical application in non …

Discovery of the epidermal growth factor receptor gene mutation and the anaplastic
lymphoma kinase chromosomal translocation in non-small cell lung cancer has prompted …